Trial Profile
A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Navitoclax (Primary) ; Venetoclax (Primary) ; Dexamethasone; Pegaspargase; Protein tyrosine kinase inhibitors; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 08 Dec 2020 Results (As of June 23, 2020; n=18) safety and efficacy of Venetoclax and Navitoclax in pediatric patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 08 Dec 2020 Status changed from active, no longer recruiting to completed.
- 21 Jun 2020 Results (n=46; as of 8 Nov 2019) presented at the 25th Congress of the European Haematology Association.